FDA Issues Draft Guidance on Chemical Analysis for Devices

The FDA issued draft guidance on September 19, 2024, concerning its recommendations related to chemical analysis for biocompatibility assessment of medical devices. This guidance will remain open for comment until December 19, 2024, as extended. This document when finalized is for guidance purposes only and alternative approaches to chemical analysis for biocompatibility assessment of medical devices remain acceptable.

How Should Manufacturers Approach FDA Chemical Analysis for Biocompatibility Testing?

When developing their approach to biocompatibility assessment requirements for their medical devices, manufacturers must consider the methods they will use for analytical testing. The FDA provides guidance on the use of chemical characterization as one approach and provides details related to the methods for analytical chemistry testing of medical devices. The guidance provides manufacturers with details related to what information is needed to begin the assessment which includes such things as the device and device components, materials, test articles and control of test articles.

In addition, the guidance provides useful information for the extraction of the test article providing parameters related to the number of extraction replications, extraction volume, temperature, time and particulates. In addition, it provides valuable detail related to the overall chemical analysis and data reporting.

The draft guidance and comment instructions can be found here.

_____________________________________________

If you need guidance on meeting FDA chemical analysis requirements for biocompatibility assessments or have questions about the draft guidance, consult the FDA’s resource center or contact us for assistance.

Learn How MedEnvoy Can Assist You:

• • US FDA Agent
  • US FDA Consulting
  • RA Consulting
  • QA Consulting